Metabolic5AM
Single or box
Loading product
Loading product
Metabolic · Research material
Package information
For product inquiries and additional information, contact lonestarpeptideco@gmail.com.
Compliance notice: For laboratory research use only. Not for human or veterinary use.
Product information is intended for laboratory, academic and commercial researchers aged 18 or over.
Material profile
A 39-residue synthetic peptide built on the GIP backbone with alpha-aminoisobutyric acid at positions 2 and 13 and a C20 diacid chain attached to lysine 20. Supplied as a lyophilized powder at 100 mg in one vial. A box of 10 is available as an optional package. It is stocked as a reference material for receptor-binding assays, LC-MS method development and in-vitro screening panels. For laboratory research use only. Not for human or veterinary use.
Catalog record
| Product | Tirzepatide — 100 mg |
|---|---|
| Catalog SKU | TR100 |
| Compound | Tirzepatide |
| Appearance | Lyophilized white powder |
| Fill per vial | 100 mg |
| Storage condition | -20 °C, desiccated, protect from light |
Laboratory handling
Ships as a sealed, stoppered lyophilized vial under insulated cold pack. Hold at -20 degrees C, desiccated and protected from light; acylated peptide analogues of this class are hygroscopic and will pick up atmospheric moisture if the stopper seal is broken. Allow vials to equilibrate to ambient temperature before the seal is opened, and follow the receiving laboratory's own written handling and disposal protocols.
Evidence first
This listing does not currently publish lot-specific analytical results. Request and review the applicable documentation before using the material in laboratory work.
Published literature
Tirzepatide is a synthetic 39-amino acid peptide (molecular weight 4810.52 Da) engineered as a dual agonist, combining the bioactive sequence of glucose-dependent insulinotropic polypeptide (GIP) with substitutions enabling activity at the GLP-1 receptor, plus a C20 fatty di-acid moiety that confers albumin binding. Published receptor pharmacology studies describe tirzepatide as an imbalanced and biased dual agonist: it engages the GIP receptor to a greater degree than the GLP-1 receptor, and at the GLP-1 receptor it is biased toward cAMP generation over β-arrestin recruitment relative to native GLP-1. Tirzepatide is an approved prescription drug; this entry addresses only molecular structure and receptor binding pharmacology and does not summarize clinical-trial or body-composition outcome data.
Describes what the cited studies examined in the systems noted above — not a claim about outcomes for people. Not medical advice.
Product support
No downloadable certificate is currently attached to this listing. Email lonestarpeptideco@gmail.com if your laboratory requires lot-specific documentation for review.
Use the package selector to review the single-vial and box-of-10 formats, then use Email to inquire if you want to ask about that product.
The catalog storage condition is -20 °C, desiccated, protect from light. Follow the handling information on this page and your laboratory's written procedures.
No. It is presented only as laboratory research material and is not for human or veterinary use, food, drugs, cosmetics, household use, or self-administration.
Catalog navigation
Other catalog records grouped under the same editorial collection.
Product inquiries
Contact Lone Star Peptide Co. for product information and inquiries.
Email to inquireRequired notice
For laboratory research use only. Not for human or veterinary use, food, drugs, cosmetics, household use, or self-administration. Product information is provided for material identification, handling, and analytical documentation; it is not medical advice or a statement of clinical safety or effectiveness.
